Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Orange, California, USA.
J Obstet Gynaecol Res. 2020 Jun;46(6):828-843. doi: 10.1111/jog.14228. Epub 2020 May 14.
Minimally invasive surgery for gynecologic cancers is associated with fewer postoperative complications including less blood loss and quicker recovery time compared to traditional laparotomy. The robotic platform has allowed patients access to minimally invasive surgery due to its increased utilization by gynecologic oncologists. Many surgeons have embraced the robotic platform due to its technological advances over traditional laparoscopy including high-definition 3D optics, wristed instrumentation, camera stability and improved ergonomics. While robotic surgery continues as a mainstay in the management of gynecologic cancers, it remains controversial in regards to its cost effectiveness and more recently, its long-term impact on clinical and oncologic outcomes. A strong component of the justification of this surgical platform is based on extrapolated data from traditional laparoscopy despite limited prospective randomized trials for robotic-assisted surgery. In this review, we highlight the use of robotic surgery in the management of gynecologic cancers in special populations: fertility sparing patients, the morbidly obese, the elderly, and patients with a favorable response to neoadjuvant chemotherapy.
与传统的剖腹手术相比,妇科癌症的微创手术具有更少的术后并发症,包括出血量少和恢复时间更快。机器人平台使妇科肿瘤医生能够更多地应用微创手术,从而使患者能够接受微创手术。许多外科医生因其在传统腹腔镜手术基础上的技术进步,包括高清 3D 光学、腕式器械、摄像机稳定性和更好的人体工程学而接受了机器人平台。虽然机器人手术仍然是妇科癌症治疗的主要方法,但它在成本效益方面仍然存在争议,最近在其对临床和肿瘤学结果的长期影响方面也存在争议。这种手术平台的合理性的一个重要组成部分是基于从传统腹腔镜手术中推断出来的数据,尽管机器人辅助手术的前瞻性随机试验有限。在这篇综述中,我们重点介绍了机器人手术在特殊人群中治疗妇科癌症的应用:有生育保留需求的患者、病态肥胖患者、老年患者和对新辅助化疗有良好反应的患者。